Skip to content

HemoCue participates at World Expo 2025

Your global partner at
the point-of-care

For more than four decades we’ve been advancing what’s possible at the point of care.​

We deliver foundational diagnostic solutions and collaborate across the healthcare industry to turn diagnostics data into insights that improve global health. Our focus spans several key health areas, including anemia, diabetes and WBC monitoring.

With a strong focus on the human touch and essential diagnostics, our purpose is to help healthcare providers make fast, informed decisions that improve lives worldwide.

At World Expo 2025, HemoCue is showcasing this commitment to innovation and global health which you can read more about below.

 

Contact us

Proud partner of World Expo 2025 in Osaka, Japan

April 13th marked the official opening of World Expo 2025 in Osaka, Japan — one of the world’s largest international exhibitions and a global platform for innovation, sustainability, and cross-cultural collaboration.

This global event offers a valuable opportunity to strengthen relationships between Sweden and Japan and deepen our collaboration with long-standing partner AMCO.

For HemoCue, it’s a chance to spotlight our innovative solutions — such as patient-friendly blood monitoring for compliant clozapine treatment made possible through WBC DIFF — while also emphasizing the critical role of sustainable partnerships in driving meaningful impact.

World Expo 2025 runs until October 13, 2025.

 

 

 

 

Read more about World Expo here

Health and well-being week

On June 27 2025, HemoCue will participate in the Health and Well-being Week at World Expo 2025 in Osaka, Japan. This theme week brings together global leaders, innovators, and partners to explore solutions that advance health equity, strengthen healthcare systems, and improve quality of life across all communities.

As a trusted partner in point-of-care diagnostics, we are honored to showcase how our solutions support faster decision-making and better health outcomes. Join us as we share our commitment to advancing care and creating healthier futures.

Read more about the theme week here.

If you are attending World Expo this week, make sure to register for HemoCue’s presentation on June 27th below.

 

HemoCue’s Agenda

Welcome to a dialogue on “Mental Health Around the World”  

In partnership with HemoCue AB and our longstanding partner in Japan, Amco Inc.

  • Exhibition of HemoCue’s products Hb 801 and WBC DIFF
  • Streamed presentation on with Jimmi Nielsen, MD, DMSC
  • Information about patient-friendly blood monitoring for compliant clozapine treatment

 

 

 

Register for HemoCue's presentation here

Our purpose

Advancing care,
test by test,
everywhere

Our applications

Blood monitoring for compliant clozapine treatment

Clozapine treatment requires mandatory blood monitoring of white blood cell counts and absolute neutrophil count.1

The HemoCue® WBC DIFF System brings the unique possibility to test and receive reliable results right at the point of care, increasing the likelihood of successful monitoring while creating a safe space for the patient.

 

Go to the product page to learn more

Improving quality control through hemolysis detection

In the laboratory, hemolysis is an important preanalytical factor that affects the accuracy and clinical utility of many test results. By assessing the degree of hemolysis before analysis, the sample can be accepted or rejected—ensuring better quality control (QC).

The HemoCue® Plasma/Low Hb System makes it possible to easily and accurately estimate hemolysis, without having to send the sample to a lab. This supports immediate QC decisions and helps maintain testing reliability from the start.

Go to the product page to learn more

Hb point-of-care testing for anemia

Hemoglobin and white blood cell (WBC) counts are important indicators of health, providing critical insights for conditions like anemia

The HemoCue® Hb 801 System takes Hb point-of-care testing to a new level. The system provides quick and easy access to lab-quality results without compromising accuracy, even in demanding climates with high temperatures and humidity. With lab-quality results in less than 1 second, you can maximize time with your patients.

Go to the product page to learn more

Enhance your patient safety and simplify your workflow

Performing hemoglobin tests at the point of care enhances the clinical evaluation of primary care patients.

The HemoCue® Hb 201 DM System offers the lab accuracy and ease of use that has become a standard in Hb point-of-care testing, while also providing improved patient safety with features like QC lockout and built-in barcode scanning of patient ID.

Go to the product page to learn more

 

“At HemoCue, we are proud to be part of a global platform like Expo 2025, as it allows us to demonstrate how cross-border collaboration can drive real change.”

Kasper Schweitz, President at HemoCue.

 

“World Expo is a remarkable opportunity for sustainable strong relationships between Sweden and Japan, and together with our partner AMCO, explore meaningful local and global partnerships.”

Lena Wahlhed, Director Alliance Development at HemoCue.

The Nordic Circle

World Expo 2025 also serves as a platform for leading Nordic companies to come together and showcase innovation. HemoCue is present alongside prominent Swedish companies including, but not limited to, Getinge, Elekta, SOBI, Saab, Tetra Pak, Volvo and Alfa Laval.

Together with companies within the Nordic region, including Novo Nordisk Foundation, we are part of The Nordic Circle — a shared pavilion highlighting innovation and sustainable solutions.

Read more here

FAQs

You can visit our product page to learn more about our products in our different areas:

Hematology: https://hemocue.com/en/products/hematology/

Diabetes: https://hemocue.com/en/products/diabetes/

Optional items: https://hemocue.com/en/products/optional-items/

You can find instructional videos for all systems at our Knowledge Center.

Read more about our accuracy and precision under “Our Accuracy” above, or access HemoCue OnCue™ Education here to learn more: https://hemocue.com/us/knowledge-center/#e-learning  

References

1  European Medicines Agency (EMA), 2002. Committee for proprietary medicinal products (CPMP): summary information on referral opinion following arbitration pursuant to article 30 of council directive 2001/83/EC for Leponex and associated names. https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-leponex-and-associated-names-international-non-proprietary-name-inn-clozapine-background_en.pdf Accessed October 28, 2024.